USRM (US Stem Cell) Forward Dividend Yield %: 0.00% (As of Jun. 26, 2026)


USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell Forward Dividend Yield %?

US Stem Cell USRM -99.00% 12 Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus rates USRM with a GF Score™ of 12/100.

As of today (2026-06-26), the Forward Annual Dividend Yield of US Stem Cell is 0.00%.

As of today (2026-06-26), the Trailing Annual Dividend Yield of US Stem Cell is 0.00%.

USRM's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.525
* Ranked among companies with meaningful Forward Dividend Yield % only.

US Stem Cell's Dividends per Share for the three months ended in Dec. 2022 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

US Stem Cell  (OTCPK:USRM) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

US Stem Cell Forward Dividend Yield % Related Terms

USRM vs NOVNQ, RGRX, NMTRQ: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, US Stem Cell's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

US Stem Cell Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, US Stem Cell's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where US Stem Cell's Forward Dividend Yield % falls into.


USRM
12GF Score
US Stem Cell Inc USRM
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Stem Cell Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
US Stem Cell (USRM) has a Forward Dividend Yield % of 0.00% as of Jun. 26, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on US Stem Cell and its competitors.
Is US Stem Cell's Forward Dividend Yield % too high?
US Stem Cell's current Forward Dividend Yield % is 0.00%. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's Forward Dividend Yield % compare to NOVNQ and RGRX?
US Stem Cell's Forward Dividend Yield % of 0.00% can be compared against companies in the Biotechnology industry. The industry median Forward Dividend Yield % is 1.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.53, based on 146 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on US Stem Cell and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. US Stem Cell's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For US Stem Cell (USRM), the current Forward Dividend Yield % is 0.00% as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price